Novel Prophylactic Vaccine Using a Prime-Boost Method and Hemagglutinating Virus of Japan-Envelope against Tuberculosis. (27th January 2011)

• Record Type: Journal Article
• Authors: Okada, Masaji; Kita, Yoko; Nakajima, Toshihiro; Kanamaru, Noriko; Hashimoto, Satomi; Nagasawa, Tetsuji; Kaneda, Yasufumi; Yoshida, Shigeto; Nishida, Yasuko; Nakatani, Hitoshi; Takao, Kyoko; Kishigami, Chie; Nishimatsu, Shiho; Sekine, Yuki; Inoue, Yoshikazu; McMurray, David N.; Sakatani, Mitsunori
• Other Names: West Nicholas Academic Editor.
• Is Part Of: Clinical & developmental immunology. Volume 2011(2011)
• Publication Date: 2011-01-27
• Subjects: Developmental immunology -- Periodicals; Clinical immunology -- Periodicals; Immune System -- immunology -- Periodicals; Immune System -- growth & development -- Periodicals; Immune System Diseases -- immunology -- Periodicals; 571.9638
• DOI: 10.1155/2011/549281
• Languages: English
• ISSNs: 1740-2522

Abstract

Abstract : Objective . Mycobacterium tuberculosis infection is a major global threat to human health. The only tuberculosis (TB) vaccine currently available is bacillus Calmette-Guérin (BCG), although it has no efficacy in adults. Therefore, the development of a novel vaccine against TB for adults is desired. Method . A novel TB vaccine expressing mycobacterial heat shock protein 65 (HSP65) and interleukin-12 (IL-12) delivered by the hemagglutinating virus of Japan- (HVJ)- envelope was evaluated against TB infection in mice. Bacterial load reductions and histopathological assessments were used to determine efficacy. Results . Vaccination by BCG prime with IgHSP65+murine IL-12/HVJ-envelope boost resulted in significant protective efficacy (>10, 000-fold versus BCG alone) against TB infection in the lungs of mice. In addition to bacterial loads, significant protective efficacy was demonstrated by histopathological analysis of the lungs. Furthermore, the vaccine increased the number of T cells secreting IFN- γ . Conclusion . This vaccine showed extremely significant protection against TB in a mouse model, consistent with results from a similar paper on cynomolgus monkeys. The results suggest that further development of the vaccine for eventual testing in clinical trials may be warranted.